Diabetes & metabolism journal · 2020
The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea.
СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Mi Kyung, Jeon Jae Han, Kim Sung Woo, Moon Jun Sung, Cho Nan Hee, Han Eugene, You Ji Hong, Lee Ji Yeon, Hyun Miri, Park Jae Seok, Kwon Yong Shik, Choi Yeon Kyung, Kwon Ki Tae, Lee Shin Yup, Jeon Eon Ju, Kim Jin Woo, Hong Hyo Lim, Kwon Hyun Hee, Jung Chi Young, Lee Yin Young, Ha Eunyeoung, Chung Seung Min, Hur Jian, Ahn June Hong, Kim Na Young, Kim Shin Woo, Chang Hyun Ha, Lee Yong Hoon, Lee Jaehee, Park Keun Gyu, Kim Hyun Ah, Lee Ji Hyun
Аннотация
BACKGROUND: Coronavirus disease 2019 (COVID-19) is a global pandemic that had affected more than eight million people worldwide by June 2020. Given the importance of the presence of diabetes mellitus (DM) for host immunity, we retrospectively evaluated the clinical characteristics and outcomes of moderate-to-severe COVID-19 in patients with diabetes.
METHODS: We conducted a multi-center observational study of 1,082 adult inpatients (aged ≥18 years) who were admitted to one of five university hospitals in Daegu because of the severity of their COVID-19-related disease. The demographic, laboratory, and radiologic findings, and the mortality, prevalence of severe disease, and duration of quarantine were compared between patients with and without DM. In addition, 1:1 propensity score (PS)-matching was conducted with the DM group.
RESULTS: Compared with the non-DM group (n=847), patients with DM (n=235) were older, exhibited higher mortality, and required more intensive care. Even after PS-matching, patients with DM exhibited more severe disease, and DM remained a prognostic factor for higher mortality (hazard ratio, 2.40; 95% confidence interval, 1.38 to 4.15). Subgroup analysis revealed that the presence of DM was associated with higher mortality, especially in older people (≥70 years old). Prior use of a dipeptidyl peptidase-4 inhibitor or a renin-angiotensin system inhibitor did not affect mortality or the clinical severity of the disease.
CONCLUSION: DM is a significant risk factor for COVID-19 severity and mortality. Our findings imply that COVID-19 patients with DM, especially if elderly, require special attention and prompt intensive care.
METHODS: We conducted a multi-center observational study of 1,082 adult inpatients (aged ≥18 years) who were admitted to one of five university hospitals in Daegu because of the severity of their COVID-19-related disease. The demographic, laboratory, and radiologic findings, and the mortality, prevalence of severe disease, and duration of quarantine were compared between patients with and without DM. In addition, 1:1 propensity score (PS)-matching was conducted with the DM group.
RESULTS: Compared with the non-DM group (n=847), patients with DM (n=235) were older, exhibited higher mortality, and required more intensive care. Even after PS-matching, patients with DM exhibited more severe disease, and DM remained a prognostic factor for higher mortality (hazard ratio, 2.40; 95% confidence interval, 1.38 to 4.15). Subgroup analysis revealed that the presence of DM was associated with higher mortality, especially in older people (≥70 years old). Prior use of a dipeptidyl peptidase-4 inhibitor or a renin-angiotensin system inhibitor did not affect mortality or the clinical severity of the disease.
CONCLUSION: DM is a significant risk factor for COVID-19 severity and mortality. Our findings imply that COVID-19 patients with DM, especially if elderly, require special attention and prompt intensive care.
Предметные рубрики MeSH
AdultAgedAged, 80 and overAlanine TransaminaseAngiotensin-Converting Enzyme InhibitorsAspartate AminotransferasesBetacoronavirusC-Reactive ProteinCOVID-19Case-Control StudiesComorbidityCoronavirus InfectionsDiabetes MellitusDipeptidyl-Peptidase IV InhibitorsFemaleHumansLength of StayLogistic ModelsLymphocytosisMaleMiddle AgedMultivariate AnalysisPandemicsPneumonia, ViralPrognosisPropensity ScoreProportional Hazards ModelsQuarantineRepublic of KoreaRisk FactorsSARS-CoV-2Severity of Illness IndexThrombocytopenia